Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Trends Cardiovasc Med. 2014 Jun 12;24(6):232–240. doi: 10.1016/j.tcm.2014.06.002

Figure 1.

Figure 1

Kaplan-Meier Estimates of the Primary Composite End Point, EDTA Chelation Therapy vs placebo.

HR indicates hazard ratio. The primary end point was a composite of death from any cause, reinfarction, stroke, coronary revascularization, or hospitalization for angina.

Adapted with permission from

The Journal of the American Medical Association:

“Gervasio A. Lamas, MD Christine Goertz, DC, PhD Robin Boineau, MD, MA Daniel B. Mark, MD, MPH Theodore Rozema, MD Richard L. Nahin, PhD, MPH Lauren Lindblad, MS Eldrin F. Lew is, MD, MPH Jeanne Drislco M, Kerry L. Lee P for the TI. Effect of Disodium EDTA Chelation Regimen on Cardiovascular Events in Patients With Previous Myocardial Infarction: The TACT Randomized Trial. JAMA. 2013;309:1241”